Computational platform for screening small molecule binders of glycosaminoglycans using Robosample and AlGDock

Overview

This solution offers a computational screening platform that combines two software packages, Robosample and AlGDock, to predict and rank small molecule compounds that bind to glycosaminoglycans (GAGs). GAGs are complex carbohydrate polymers involved in numerous biological processes and are of growing interest as therapeutic targets. The platform addresses the challenge of accurately modeling polysaccharide-small molecule interactions, which are difficult to handle with conventional protein-focused docking tools. By pairing a sampling engine optimized for glycans with a rigorous free energy scoring method, the platform enables partners to efficiently prioritize candidate binders before committing to experimental testing.

Technical specifications

Key components and capabilities:

• Robosample performs rigid-body conformational sampling of glycosaminoglycans, generating physically realistic configurations of these polysaccharide structures
• AlGDock calculates binding free energies between candidate small molecules and the sampled GAG configurations, providing quantitative affinity predictions
• The combined workflow delivers both classification of binders versus non-binders and, where experimental data are available, quantitative affinity estimates
• Performance is evaluated using receiver operating characteristic (ROC) analysis to measure discrimination between known binders and non-binders
• The approach has prior validation on protein-ligand systems and demonstrated suitability for glycan sampling, making it a promising extension to GAG-small molecule screening

Technology readiness level

The platform is built on two established, published software tools: Robosample, which has been demonstrated suitable for glycan sampling, and AlGDock, which has been validated on protein-ligand binding free energy calculations. The current stage involves prospective validation with an industry partner, in which known binders and non-binders will be scored computationally and compared against experimental data. This validation phase will confirm the platform's accuracy and reliability for GAG-targeted drug discovery applications.